PDF herunterladen
Open Access
CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0045-1815733
Review Article

Exploring the Outcomes of Hodgkin Lymphoma in Pediatric Patients: A Systematic Review from India

Autor*innen

  • Chandrika Verma

    1   Department of Pediatric Hematology Oncology, Indraprastha Apollo Hospital, New Delhi, India

  • Kushagra Taneja

    1   Department of Pediatric Hematology Oncology, Indraprastha Apollo Hospital, New Delhi, India

  • Amita Mahajan

    1   Department of Pediatric Hematology Oncology, Indraprastha Apollo Hospital, New Delhi, India

  • Ramandeep Arora

    2   Department of Paediatric Oncology, Max Super Speciality Hospital, New Delhi, India

Funding None.
Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints

Abstract

Hodgkin lymphoma (HL) has emerged as one of the most curable pediatric cancers globally. However, in low- and middle-income countries like India, the treatment landscape is shaped by various biological, social, and resource-related factors, leading to variability in management approaches and outcomes. This systematic review aims to bring together the available data to provide an integrated overview of current management practices and outcome of childhood HL in India. Thirteen studies were reviewed, including 3 multicenter studies, with a total cohort of 1,766 children. The median age at diagnosis ranged from 7 to 10 years, with male-to-female ratios between 2.8:1 and 10.5:1. A significant proportion (70–80%) of children presented with advanced stages of the disease. Utilization of positron emission tomography-computed tomography for assessment was inconsistent across centers, and the use of radiotherapy (RT) varied widely. Most centers have reported 5-year overall survival and 5-year event-free survival of approximately 90% and above and 75 to 85%, respectively. Adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) was the most widely used regimen; however, recent studies have used vincristine, etoposide, prednisolone, doxorubicin (OEPA)/cyclophosphamide, vincristine, prednisolone, dacarbazine (COPDAC) with the intent to reduce long-term side effects associated with radiation exposure. Treatment-related mortality of around 5% was noted with OEPA/COPDAC in Indian setting in contrast to ABVD, which is close to 1%. Feasibility and long-term benefits of the former chemotherapy need further follow-up. Challenges such as treatment abandonment and toxic deaths remain significant, and there is a notable lack of data on long-term outcomes and late effects, necessitating further research in these areas.

Keywords

abandonment - Hodgkin lymphoma - pediatric - overall survival

Authors' Contributions

R.S.A. conceptualized the study, supervised the work, and critically reviewed the manuscript. K.T. collected the data, searched literature, and analyzed the data. Analysis of the articles was done by two independent reviewers (C.V. and R.S.A.). K.T. and C.V. integrated and interpreted the data and cowrote the manuscript. All authors discussed the results and approved the final draft.


Patient Consent

Patient consent is not required.




Publikationsverlauf

Artikel online veröffentlicht:
20. Januar 2026

© 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India